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Abstract
Calpains are non-lysosomal, Ca2q-dependent cysteine
proteases, which are ubiquitously distributed across cell
types and vertebrate species. The rules that govern cal-
pain specificity have not yet been determined. To eluci-
date the cleavage pattern of calpains, we carried out
calpain-induced proteolytic studies on the insulin-like
growth factor binding proteins IGFBP-4 and -5. Proteol-
ysis of IGFBPs is well characterized in numerous reports.
Our results show that calpain cleavage sites are in the
non-conserved unstructured regions of the IGFBPs.
Compilation of the calpain-induced proteolytic cleavage
sites in several proteins reported in the literature, togeth-
er with our present study, has not revealed clear prefer-
ences for amino acid sequences. We therefore conclude
that calpains seem not to recognize amino acid sequenc-
es, but instead cleave with low sequence specificity at
unstructured or solvent-exposed fragments that connect
folded, stable domains of target proteins.
Keywords: calpain; Ca2q-dependent cysteine protease;
calpastatin; insulin-like growth factor binding protein.
Introduction
Calpains are a large family of Ca2q-dependent cysteine
proteases ubiquitously expressed in mammalian cells.
The two major mammalian calpains are designated
m-calpain and m-calpain based on their in vitro activa-
tion, which requires micromolar and millimolar concen-
trations of Ca2q, respectively (Goll et al., 2003). The two
enzymes appear to be very similar in many biochemical
properties and their structures also show a similar folding
pattern (Pal et al., 2003) but significant differences are
observed in the catalytic triad of residues of these two
isoforms (Strobl et al., 2000). Calpains are heterodimers
composed of a large catalytic subunit of 80 kDa (con-
taining domains I–IV) and a small 28-kDa regulatory
subunit (composed of domains V and VI). The small
subunit is identical in both isoforms, but the large subu-
nits are generated by two different genes (Dear and
Boehm, 2001; Sorimachi and Suzuki, 2001; Goll et al.,
2003). Activation of the protease core of m-calpain
requires cooperative binding of two Ca2q atoms at two
non-EF-hand sites (Khorchid and Ikura, 2002; Moldovea-
nu et al., 2002, 2004). Substantial evidence indicates that
calpains play a crucial role in a diverse spectrum of cel-
lular responses, which include cell differentiation, apop-
tosis, cytoskeletal remodeling, signal transduction and,
most recently identified, cell adhesion and motility (Croall
and Demartino, 1991; Sato and Kawashima, 2001; Gla-
ding et al., 2002; Goll et al., 2003). Although definitive
physiological roles are not yet established, dysregulated
Ca2q levels result in aberrant proteolysis by calpains,
which contributes to tissue damage in heart and brain
ischemia, cerebral infarction, acute neurological disor-
ders such as stroke and, more recently identified, to Alz-
heimer’s disease (Huang and Wang, 2001). Calpains have
been also identified as a susceptible gene in type 2 dia-
betes (Kuwaki et al., 1989). Calpains are generally
believed to exist and function in the cytoplasm, but a few
studies have reported the existence of m-calpain in the
extracellular spaces of various tissues (Glading et al.,
2001; Nishihara et al., 2001). Immunolocalization studies
have shown extracellular localization of calpains in dis-
eased states (Kumamoto et al., 1992).
The rules that govern calpain specificity have not yet
been determined. In this paper we attempt to character-
ize calpain preferred cleavage positions in the insulin-like
growth factor binding proteins (IGFBPs). We have chosen
to use these proteins for our calpain study for two rea-
sons. First, proteolysis of IGFBPs is extensively charac-
terized by numerous reports; this is because limited
proteolysis of IGFBPs is the major mechanism for the
release of IGFs from IGFBP/IGF complexes, generating
IGFBP fragments with reduced affinity for IGFs (Binoux
et al., 1999; Khandwala et al., 2000). This thereby
increases the concentration of IGFs at the cell surface
and allows IGFs to bind and activate the IGF receptor
(Bunn and Fowlkes, 2003). Secondly, IGFBPs are struc-
turally well characterized; they are composed of globular
domains linked by large flexible fragments, thus provid-
ing model proteins that contain diverse structural ele-
ments (Kalus et al., 1998).
IGFBPs are also active in the cellular environment, as
they may regulate cells by IGF-independent mechanisms
(Oh and Rosenfeld, 1999; Baxter, 2000; Firth and Baxter,
2002). The effects of intracellular IGFBPs are complex,
however, with both stimulatory and inhibitory actions. In
addition, the regulation of intracellular IGFBPs by prote-
ases influences the IGFBP extracellular concentration.
Proteolytically cleaved fragments of the same IGFBP pro-
tein may display different cellular localizations. Several
studies have identified IGFBP-3 in cell nuclei or directly
demonstrated its nuclear transport by an importin b-
mediated mechanism (Jaques et al., 1997; Wraight et al.,
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Figure 1 SDS-PAGE analysis of fragments generated by cal-
pain cleavage.
(A) SDS-PAGE analysis of IGFBP-4 proteolysis by m-calpain.
Lane 1 contains aliquots of the undigested protein as the con-
trol. Lanes 2–5 contain aliquots of the digestion reaction of
IGFBP-4 cleavage at different calpain concentrations (20, 50,
100 and 250 nM) in the calpain assay buffer. Lane 6 shows the
prestained molecular mass protein marker (kDa).
(B) SDS-PAGE analysis of IGFBP-5 digested by m-calpain. Lane
1 shows the prestained marker. Lane 2 contains the undigested
IGFBP-5 protein. Lanes 3–7 show IGFBP-5 cleavage at different
time intervals of 0 min, 30 min, 1 h, 2 h, and 4 h, respectively,
at a constant calpain concentration of 20 nM in the calpain reac-
tion buffer. IGFBP-4 is a 28-kDa protein and IGFBP-5 is 28.5 kDa
in molecular mass.
Figure 2 IGFBP stability gel showing the protein at different
time intervals.
Lane M shows the prestained molecular mass protein marker
(kDa) and the remaining lanes contain aliquots of the protein in
the calpain assay buffer at different time intervals. The protein
remains stable even after 3 days.
1998). Competition studies suggested that IGFBP-5 uses
the same nuclear transport system as IGFBP-3 (Sched-
lich et al., 1998). We have studied the calpain-induced
proteolysis of two members of the IGFBP family (IGFBP-
4 and IGFBP-5) in this paper. We expect, however, that
calpain proteolysis will be very similar for other IGFPBPs
because of the amino acid sequence and structural sim-
ilarities of these proteins.
Results
The sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) analysis of the in vitro assay clearly
showed that there were calpain cleavage sites in both
IGFBP-4 and IGFBP-5 and both proteins were rapidly
cleaved into smaller fragments (Figure 1A, B). For
1000 nM IGFBPs, as little as 20 nM m-calpain was suffi-
cient to induce cleavage and a further increase in the
protease concentration up to 250 nM did not result in any
change in the cleavage pattern. In addition, there was no
change observed with increasing time: cleavage patterns
obtained within the first 30 min were the same as those
obtained after 4 h. This was expected, as calpain is an
autolytic enzyme (Tompa and Friedrich, 2000; Li et al.,
2002) and autolyses within the first 30 min, which results
in protease activation, but an increased time interval
does not result in any extra cleavage sites, which shows
that calpain-mediated proteolysis is limited. The IGFBP
protein stability assays showed that the proteins were
stable and did not degrade at room temperature for up
to 48 h, as shown in Figure 2. Figure 3A shows the West-
ern blot analysis of IGFBP cleavage products after diges-
tion with 20 nM m-calpain. Figure 3B shows the results
of the inhibitory assay of the endogenous protein inhibi-
tor of calpains, calpastatin (Goll et al., 2003). Calpastatin
efficiently blocked the cleavage of both IGFBP-4 and
IGFBP-5, as no cleavage fragments of the proteins were
observed. Domain I of calpastatin was chosen for the
experiment as it inhibits m- or m-calpain to a greater
extent compared to other domains (Goll et al., 2003). This
result clearly indicates that the cleavage pattern
observed was entirely due to calpain and not to any other
contaminating protease. In addition, no cleavage was
observed in the absence of calcium, in agreement with
the fact that calcium is necessary to induce the autocat-
alytic activity of calpain.
Characterization of the cleavage sites in IGFBPs was
accomplished by subjecting proteolytic products to NH2-
terminal sequencing by Edman degradation. The amino
acid sequences obtained for IGFBP-4 were: GSSHH,
A3IHC, M73HGQG, A87IQESL, A123KIR, and G139APR.
Exact molecular weights of the isolated fragments were
determined by matrix-assisted laser desorption/ioniza-
tion-mass spectrometry (MALDI-MS). Similarly, for
IGFBP-5, the amino acid sequences obtained from the
N-terminal sequencing were: S3FVH, C8EPCD, Q142SKFV,
and A153HPRI. The results of the fragments generated
from polyvinylidene fluoride (PVDF) analysis and reverse-
phase HPLC were mapped onto the IGFBP-4 and
IGFBP-5 sequences and all the theoretically possible
cleavage fragments for both IGFBPs were simulated.
Mass spectrometry showed that fragments of the fol-
lowing sizes were generated for IGFBP-4: 14.75, 13.10,
11.01, 10.90, 4.10, and 2.45 kDa (Figure 4A). For IGFBP-
5, fragments of 15.69, 16.81, 12.70, and 11.60 kDa were
obtained (Figure 4B). These mass spectrometry results,
together with the results from N-terminal sequencing,
identified cleavage sites at amino-acid positions 2, 86,
122, and 138 in IGFBP-4 (Figure 5). Hence, in IGFBP-4
calpain appears to act on the bond between Glu 2 and
Ala 3, generating a fragment of approximately 2.45 kDa,
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Figure 3 Western blot analysis and calpastatin inhibitory assay.
(A) Western blot of IGFBP fragments generated by m-calpain
protease cleavage. IGFBP digested with calpain was resolved
by SDS-PAGE and transferred onto a nitrocellulose membrane.
Cleaved fragments of IGFBP were detected by immunoassaying
with IGFBP polyclonal antibodies. Lane 1 shows the prestained
marker. Lanes 2–5 highlight the cleavage products of IGFBP.
Lane 6 consists of the undigested IGFBP protein as control.
(B) Calpastatin inhibitory and Ca2q-dependent protease assay.
Lanes 1 and 7 show the molecular weight protein marker. Lane
2 shows IGFBP protein incubated with the protease, m-calpain
and calpastatin in the absence of Ca2q, where no cleavage
occurs. Lanes 3 and 5 contain aliquots of IGFBP-4 and IGFBP-
5, respectively, digested with 20 nM m-calpain in the absence of
calpastatin and supplemented with 1 mM Ca2q. Lanes 4 and 6
show the inhibition of the IGFBP-4 and -5 cleavage bym-calpain
in the presence of calpastatin at molar concentrations of 1:1 with
calpain.
Figure 5 Summary of the location of the principal calpain
cleavage sites in IGFBP-4 and IGFBP-5.
Figure 4 Schematic representation of the fragments generated
by calpain cleavage.
Fragments for IGFBP-4 (A) and IGFBP-5 (B).
which corresponds to the 20 His/T7-tag, residues along
with the first three residues of the amino terminus of the
protein. The other three major cleavage sites were found
in the weakly conserved regions of the protein at Glu 86
and Ala 87, generating fragments of approximately 11.01
and 16.0 kDa. There was another small fragment of
4.10 kDa observed in mass spectrometry instead of the
large 16.0-kDa fragment. This discrepancy arose
because this larger fragment was further cleaved at
another major internal cleavage site, Phe 122 and Ala
123, which generated fragments of 4.10 and 13.10 kDa.
The last major site was the bond between Asp 138 and
Gly 139, which resulted in a fragment of 10.90 kDa. The
NH2-terminal sequencing of IGFBP-4 yielded another
weak cleavage site at the bond between Leu 72 and Met
73, which corresponds to the N-terminal region of the
protein, but mass spectroscopy did not show any such
fragment with the corresponding molecular weight.
Hence, this site was not considered as a major cleavage
site.
In IGFBP-5, we identified cleavage sites at residues 2,
141, and 152, as shown in Figures 4B and 5. Three major
cleavage sites were observed: the first site is between
the residues Gly 2 and Ser 3 located at the very begin-
ning of the protein at the amino-terminus. NH2-terminal
sequencing of IGFBP-5 also showed another very close
site between His 7 and Cys 8, but this was probably due
to degradation of the N-terminus following initial cleav-
age, as no corresponding fragment was evident in the
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Figure 6 The amide region of one-dimensional NMR spectra
of the recombinant human IGFBP-5.
The upper, middle and lower panels show the full-length protein,
a C-terminal fragment of 112 (residues 135–246) and an N-ter-
minal fragment of 94 residues, respectively. The fragments were
created by limited proteolysis with endoproteinase Asp-N. A
schematic domain structure of IGFBP-5 consists of the N-ter-
minal domain (light gray), a central domain (gray) and the C-
domain (dark gray). Sticks mark cysteines.
mass spectra. The other two cleavage sites are located
in the weakly conserved domain of the protein, as in
IGFBP-4, but not at the same residues. The first, located
between Thr 141 and Gln 142, results in fragments of
15.69 and 12.70 kDa, and the second, between Thr 152
and Ala 153, generated fragments of 16.81 and
11.61 kDa.
Figure 6 shows one-dimensional 1H NMR spectra of
IGFBP-5. Inspection of such spectra yields semi-quan-
titative information on the extent of folding in proteins or
their domains (Rehm et al., 2002). The upper panel
shows the spectrum of the full-length IGFBP-5; this
spectrum exhibits a large peak at 8.3 ppm and some
signals downfield (i.e., at higher ppm values) close to the
noise level. The appearance of intensities at chemical
shifts near;8.3 ppm is an indicator of a disordered pro-
tein, as this is a region characteristic of backbone amides
in a random coil configuration (Weber et al., 2000; Rehm
et al., 2002). On the other hand, large signal dispersion
beyond 8.3 ppm proves a protein to be folded. Due to
the different chemical environment and thus the varying
shielding effects, the resonances of single protons will be
distributed over a wide range of frequencies. A typical
intensity pattern of a folded protein is shown in the lower
panel, which shows the spectrum of the N-terminal frag-
ment of IGFBP-5. The spectrum of the C-terminal frag-
ment indicates that there are also some unstructured
regions located in the C-terminal fragment (Figure 6, mid-
dle). Based on these spectra, we can conclude that the
central variable domain of IGFBP-5 is in a random coil
conformation. Nearly identical estimates were obtained
from NMR for IGFBP-3 and IGFBP-4 (data not shown).
Discussion
The IGFBP family comprises six proteins (IGFBP-1–6)
that bind to IGFs with high affinity, and a group of IGFBP-
related proteins (IGFBP-rP 1–9), which show lower affin-
ity for IGFs (Khandwala et al., 2000; Clemmons, 2001).
IGFBPs-1–6 share a high degree of similarity in their pri-
mary protein structure (identities approx. 30–40%), with
highest conservation at the N- and C-terminal regions
(Figures 6 and 7), which participate in binding to IGFs
(Baxter, 2000; Payet et al., 2003; Shand et al., 2003). The
structure of the N-terminal domain of IGFBP-5 discloses
a rigid, globular fold that consists of a centrally located
three-stranded antiparallel b-sheet (Zeslawski et al.,
2001). This is in contrast to the central, weakly conserved
domain in IGFBPs, for which the NMR spectra presented
here indicate a highly flexible, disordered conformation
(Figure 6). This domain is also the site of proteolytic activ-
ity in IGFBPs (Figure 5). Our data indicate that there are
four major calpain cleavage sites in IGFBP-4 and three
in IGFBP-5 (Figure 5) all located in this region of the pro-
tein, except for the first cleavage sites in the N-terminal
domain of both the proteins. Comparison of the cleavage
pattern of IGFBP-5 with endoproteinase Asp-N reveals
that Asp-N cleaves in a generally similar manner to cal-
pain (i.e., in the central domain of the protein); however,
the specific bonds are different (Kalus et al., 1998).
Figure 7 and Table 1 show locations of the cleavage
sites on IGFBPs found in the present study and those
compiled from the literature for other proteases. All
IGFBPs, except IGFBP-6, are highly sensitive to prote-
olysis (the resistance of IGFBP-6 may be due to the
absence of hydrophobic residues, such as tyrosine, tryp-
tophan and phenylalanine, a very small variable domain
and a low number of basic amino acid residues). Gen-
erally, for all IGFBPs two–three major proteolytic cleav-
age sites always occur at the beginning and towards the
end of the variable domain (Figure 7). Calpain follows this
rule too. Although the N- and C-terminal domains of
IGFBPs are resistant to proteolytic attack, degradation of
the C-terminal regions has been observed for IGFBP-3
(for plasmin, PSA, cathepsin D, and thrombin) and
IGFBP-5 (thrombin) in in vitro studies. Figure 7 also
includes our in vitro proteolysis of the recombinant
human IGFBP-5 (residues 158–247) with thrombin. This
fragment shows two extra cleavage sites compared to
proteolysis of a full-length IGFPB-5 at physiological con-
centrations of thrombin (Zheng et al., 1998). A corre-
sponding C-terminal region of IGFBP-4 (residues
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Figure 7 Sequence alignment of all the IGFBP non-conserved regions.
Grey, conserved amino acids; red, protease cleavage sites reported in the literature to date (see Table 1); blue, amino acids after
which calpain cleaves; green, amino acids after which endoproteinase Asp-N cleaves.
Table 1 Proteolytic cleavage sites in IGFBPs.
Protease Cleavage sites Reference
(source) (P1 residue)
IGFBP-1 Stromelysin-3 140 Manes et al., 1997
IGFBP-2 Fetal rat liver cell line 147 Wang et al., 1988
Human milk 169, 181 Ho and Baxter, 1997
IGFBP-3 Plasmin 95, 97, 149, 150, 151 Lalou et al., 1997
155, 160, 198, 220 Booth et al., 1996
PSA 97, 132, 159, 173, 179 Fielder et al., 1994
Human serum 97, 148, 149, 150, 154 Booth et al., 1996
MMP-1 99 Fowlkes et al., 1994
MMP-2 (human fibroblasts) 99 Fowlkes et al., 1994
MMP-3 99, 109, 176 Fowlkes et al., 1994
Cathepsin D 98, 159, 163, 200 Claussen et al., 1997
Thrombin 97, 206 Booth et al., 1996
MCF-7 cell line 97 Salahifar et al., 2000
IGFBP-4 Rat neuronal cells 90, 120, 132 Chernausek et al., 1995
Human fibroblasts 135 Conover et al., 1995
Cathepsin D 135 Claussen et al., 1997
Calpain (human erythrocytes) 3, 86, 122, 138 This work
IGFBP-5 Human osteoblasts 169 Andress, 1995
Porcine aortic smooth muscle cells 137, 138 Imai et al., 1997
Thrombin 120, 156, 192 Zwad et al., 2002
PAPP-A 143, 144 Laursen et al., 2001
Calpain (human erythrocytes) 2, 140, 151 This work
Asp-N 94, 134 Kalus et al., 1998
171–252) was completely resistant to thrombin proteol-
ysis in our experiments (data not shown).
Since IGFBP-3 and IGFBP-5 show structural similari-
ties and both are synthesized by cell types derived from
the mesenchyma, calpain is expected to cleave IGFBP-
3 in the same fashion as it cleaves IGFBP-5. There is
evidence that a calpain-like cysteine protease is a key
regulatory component required for passage through the
G1 phase of the cell cycle in eukaryotes (Mellgren, 1997).
As IGFBP-3 can traverse into the nucleus, calpain might
also regulate the IGF-independent functions of IGFBP-3
(Baxter, 2000).
There are a limited number of reports on the subsite
specificity of calpains and these have been reviewed by
Croall and Demartino (1991) and more recently by Goll
et al. (2003). In general, the literature data indicate that
the calpains cleave target proteins at a limited number of
sites and produce large polypeptide fragments rather
than small peptides (Sasaki et al., 1984). Early studies
suggested that the calpains preferentially cleaved pep-
tide bonds with a Leu or a Val residue in the P2 position.
More complete data, however, indicated that subsite
specificity of the calpains is controlled by the confor-
mation of the polypeptide chain and not by amino acid
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Table 2 Calpain cleavage sequences.
Protein Cleavage
Site Sequence
IGFBP-4 (this work) 2 GDEAIH
86 EIEAIQ
122 KHFAKI
138 KVNGAP
IGFBP-5 (this work) 2 SLGSFV
141 KLTQSK
152 ENTAHP
Crystallin (Shih et al., 1998)
bB1 12 ATAAVN
15 GPPPGP
bA3 11 ELESLP
17 TTKMAQ
bB2 8 QTQAGK
bB3 5 EQHSTP
10 PEQAAA
Calpain (autolysis; 9 KLAKDR
Brown and Crawford, 1993) 19 GLGSHE
Cleavage occurs after the third residue of the cleavage
sequence.
sequence (Fischer et al., 1986; Harris et al., 1988; Croall
et al., 1996; Stabach et al., 1997). For example, 9 of the
11 calpain cleavages in the a-tropomyosin polypeptide
are in the COOH-terminal half of the molecule (Goll et al.,
2003) where the COOH-terminal half of the helix is sig-
nificantly less stable than the NH2-terminal half, sug-
gesting that subsite specificity of the calpains depends
on the conformation of the polypeptide, with a more
open structure favoring cleavage.
Our present study has not revealed clear preferences
for amino acid sequences, although in many cases a
hydrophobic residue is present in the P2 position (Table
2 and Figure 7). For completeness, we also include in
Table 2 two reports not covered by the reviews (Croall
and Demartino, 1991; Goll et al., 2003). These data per-
tain to the m-calpain cleavage of N-terminal propeptides
of b-crystallin, which are highly mobile and in random coil
conformations (PDB: 1E7N; Clout et al., 2000).
In conclusion, we propose that calpains seem not to
recognize amino acid sequences in target proteins, but
cleave with low sequence specificity at unstructured or
solvent-exposed fragments that connect folded, stable
domains of target proteins, suggesting that calpains may
modulate the functions of substrate proteins by cutting
their interdomain regions.
Materials and methods
Chemicals, plasmid, expression host strain and
growth media
Unless otherwise specified, all reagents were obtained from Sig-
ma (Taufkirchen, Germany). Luria broth, agar, and antibiotics
were purchased from Sigma-Aldrich. BL21 (DE 3) E. coli protein
expression strains bought from Invitrogen (Karlsruhe, Germany)
are designed for high-level protein expression using T7 RNA
polymerase-based expression systems. pET 28a expression
vector, based on the T7 promoter-driven system, was obtained
from Novagen (Darmstadt, Germany). The restriction enzymes
NdeI and BamHI were from New England Biolabs (Frankfurt,
Germany). Pfu polymerase and DNA ligase were purchased from
Stratagene (La Jolla, USA). Antibodies and isopropyl b-D-thio-
galactoside (IPTG) were obtained from Santa Cruz Biotechnol-
ogy (Santa Cruz, USA) and Peq Labs (Erlangen, Germany),
respectively. Plasmid miniprep kit and Ni-NTA resin were bought
from Qiagen (Hilden, Germany). The nitrocellulose membranes,
polyvinylidene fluoride (PVDF) membranes and the ion exchange
and size exclusion chromatography columns were purchased
from Amersham Pharmacia Biotech (Freiburg, Germany). Brad-
ford reagent was from Bio-Rad (Munich, Germany). The ultrafil-
tration membranes used were from Amicon (Schwalbach,
Germany).
Cloning and protein expression
Human recombinant IGFBP-5 protein was a generous gift from
Roche Diagnostics (Penzberg, Germany). The IGFBP-4 cDNA
was also obtained from Roche Diagnostics in BP4-2/pFDX500
vector. To purify the protein as a His-tag fusion protein, the
IGFBP-4 cDNA (full-length residues 1–237) was subcloned into
pET-28 (a) vector (Qiagen) with restriction sites at NdeI and
BamHI in frame to a His-tag. Standard procedures were adopted
for the construction of the vector pET-28 (a) with the desired
insert (full-length IGFBP-4) which was expressed as a fusion
protein in E. coli strain BL21 (DE 3) under kanamycin
selection. The encoded amino acid sequences were
gss ssg sMDEAIH«LADSFRE wthe protein of interesthhhhhh lvprg
is shown in capital letters and the amino acids of the His-tag
and thrombin cleavage site (underlined) are in italicsx. Expression
was carried out in shaking cultures at 300 rpm and 378C. The
cultures were induced with 1 mM IPTG at a cell density of
OD600s0.85. Cells were harvested by centrifugation after 3 h of
induction.
Protein purification
The cell pellets were resuspended in lysis buffer and kept for
1 h shaking. To obtain complete lysis, the cells were sonicated
using a macro tip, with which pulsed, high-frequency sound
waves are used to agitate and lyse cells. To prevent excessive
heating, ultrasonic treatment was applied in multiple short bursts
to the sample immersed in an ice bath. The sonication was car-
ried out for 2 min at a duty cycle of 50% and output control 7.
The sonication/lysozyme treatment was carried out by first treat-
ing the cells with the lysozyme and then sonicating the extract.
All of the extracts were clarified by centrifugation for 60 min at
60 000 g at 48C. The supernatants were recovered and then ana-
lyzed for total protein by the Bradford protein assay. The super-
natant was loaded onto a Ni-NTA column and protein elution
was carried out using a pH gradient method (Qiagen). The frac-
tions containing IGFBP-4 were pooled and b-mercaptoethanol
was added at a concentration of 10 mM. The final volume was
concentrated to approximately 2 ml by ultrafiltration and then
dialyzed against 6 M guanidinium chloride. The protein solution
was then diluted into refolding buffer (Kalus et al., 1998). After
24 h of refolding at 48C, the protein solution was again concen-
trated by ultrafiltration and dialyzed against phosphate buffer
and loaded onto an anion exchange column (Mono S) in which
the proteins were bound to the column material in 25 mM phos-
phate buffer, 25 mM NaCl, pH 7.2, and bound proteins were
fractionated by a linear gradient of 25–700 mM NaCl over 20
column volumes. The fractions containing the protein were
pooled and size exclusion chromatography was carried out on
a Superdex 75 column.
m-Calpain storage conditions
m-Calpain was isolated from human erythrocytes as described
previously (Gabrijelcic-Geiger et al., 2001). The purified enzyme
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was dialyzed against 10 mM Tris, 150 mM NaCl, 1 mM EDTA,
0.2 mM phenylmethylsulfonyl fluoride (calpain storage buffer)
and stored at 48C until use. On the day of use, a small aliquot
was taken and reactivated with 14 mM b-mercaptoethanol prior
to the proteolysis assays.
IGFBP-4 and IGFBP-5 limited proteolysis assays
Purified IGFBP-4 and IGFBP-5 were incubated separately with
calpain at a molar ratio of 1:50 in calpain assay buffer (25 mM
Tris, 150 mM NaCl, pH 7.3) supplemented with CaCl2 and kept
for different time intervals at room temperature. Addition of
10 mM EDTA stopped the reactions. The fragments were sepa-
rated by SDS-PAGE and visualized by Coomassie Blue staining.
Calpastatin inhibitory and protein stability assays
Domain 1 of calpastatin was added in equimolar ratio to calpain.
Purified IGFBP-4 and IGFBP-5 were incubated separately with
calpain and calpastatin at the molar ratio of 1:50:1 (protein/cal-
pain/calpastatin) in calpain assay buffer supplemented with
CaCl2 to a final concentration of 1 mM and kept for different time
intervals at room temperature. Addition of 10 mM EDTA and
SDS-PAGE loading buffer stopped the reaction. Subsequently,
the protein fragments were separated by SDS-PAGE and visu-
alized by Coomassie blue staining. To ensure that the respective
proteins were not degrading autocatalytically and that the deg-
radation was due to calpain cleavage, we carried out a stability
test by keeping the proteins at room temperature in calpain
assay buffer without adding calpain, and taking aliquots for
SDS-PAGE at different time intervals for up to 3 days; no deg-
radation was observed, even after 3 days.
Electrophoresis and Western blot analysis
Aliquots of the protein samples treated with calpain were
resolved on 12% SDS-PAGE, which was carried out using the
Laemmli procedure. Western blot analysis was then carried out
using primary antibodies against the protein. Alkaline phospha-
tase-conjugated secondary antibodies were then used against
the primary antibody and the membrane was further developed
by incubation with 5-bromo-4-chloro-3-indolyl phosphate
(BCIP)/nitroblue tetrazolium (NBT) alkaline phosphatase sub-
strate for 15–30 min.
N-Terminal sequencing of the protein fragments
using PVDF membranes, reversed-phase HPLC and
mass spectrometry
The reaction mixtures once resolved on SDS-PAGE were used
to electroblot the protein fragments onto a PVDF membrane
using the standard procedure described by Sambrook et al.
(1989) so that the NH2-terminal amino acids of the intact and
cleaved products could be sequenced. The electroblot was car-
ried out using semi-dry electroblotting apparatus at constant
power supply of 110 mV for 1 h. The protein fragment-blotted
PVDF membrane was stained with Coomassie blue dye. Coo-
massie-stained bands were cut from the membrane and used
for N-terminal sequencing by Edman degradation. The results
obtained from the sequence analysis were then mapped on the
IGFBP sequences (Swiss-Prot, primary accession number
P22692 for IGFBP-4 and P24593 for IGFBP-5). To further con-
firm the results of N-terminal sequencing, the reaction mixtures
were purified by reverse-phase HPLC, sequenced and analyzed
by mass spectrometry using MALDI-MS.
NMR spectroscopy
Standard 1D proton spectra were acquired on a Bruker DRX 600
spectrometer at 300 K. The protein samples were typically
0.3–0.6 mM in phosphate-buffered saline (PBS).
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